The limited therapeutic options available for hepatocellular carcinoma (HCC) make mandatory to find alternative effective treatments for this tumor. Based on the recent finding that systemic or local hypothyroidism is associated with HCC development in humans and rodents, we investigated whether the thyroid hormone triiodothyronine (T3) could inhibit the progression of hepatocellular carcinomas (HCCs).
Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming
Morandi, Andrea;Merlin, Simone;Sanchez-Martin, Carlos;Rasola, Andrea;
2020
Abstract
The limited therapeutic options available for hepatocellular carcinoma (HCC) make mandatory to find alternative effective treatments for this tumor. Based on the recent finding that systemic or local hypothyroidism is associated with HCC development in humans and rodents, we investigated whether the thyroid hormone triiodothyronine (T3) could inhibit the progression of hepatocellular carcinomas (HCCs).
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Kowalik et al.pdf
accesso aperto
Tipologia:
Preprint (submitted version)
Licenza:
Accesso gratuito
Dimensione
686.81 kB
Formato
Adobe PDF
|
686.81 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
